Stem definition | Drug id | CAS RN |
---|---|---|
antibacterials, nalidixic acid derivatives | 1594 | 98079-51-7 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 1.64 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 65 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 16.26 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 97 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.04 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.98 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 8.10 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Feb. 21, 1992 | FDA |
None
None
None
None
Source | Code | Description |
---|---|---|
ATC | J01MA07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
ATC | S01AE04 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Fluoroquinolones |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D059005 | Topoisomerase II Inhibitors |
MeSH PA | D059003 | Topoisomerase Inhibitors |
CHEBI has role | CHEBI:33231 | antitubercular agents |
CHEBI has role | CHEBI:33281 | antibiotics |
CHEBI has role | CHEBI:47868 | photosensitising agent |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Bronchitis | indication | 32398004 | DOID:6132 |
Lower respiratory tract infection | indication | 50417007 | |
Klebsiella cystitis | indication | 60867007 | |
Urinary tract infectious disease | indication | 68566005 | |
Acute bacterial bronchitis | indication | 233598009 | |
Escherichia coli urinary tract infection | indication | 301011002 | |
Acute exacerbation of chronic bronchitis | indication | 425748003 | |
Urinary tract infection caused by Klebsiella | indication | 369001000119100 | |
Proteus Cystitis | indication | ||
Moraxella Catarrhalis Chronic Bronchitis | indication | ||
Staphylococcus Cystitis | indication | ||
Prevention of Infection in Transrectal Prostate Biopsy | indication | ||
Haemophilus Influenzae Chronic Bronchitis | indication | ||
Complicated Proteus UTI | indication | ||
E. Coli Cystitis | indication | ||
Complicated UTI with Pseudomonas Aeruginosa | indication | ||
Prevention of Infection from Transurethral Surgery | indication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.84 | acidic |
pKa2 | 8.18 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
DNA gyrase subunit A | Enzyme | IC50 | 5.15 | WOMBAT-PK |
ID | Source |
---|---|
4020246 | VUID |
N0000148144 | NUI |
D00873 | KEGG_DRUG |
98079-52-8 | SECONDARY_CAS_RN |
4020246 | VANDF |
4020537 | VANDF |
CHEBI:116278 | CHEBI |
CHEMBL561 | ChEMBL_ID |
CHEMBL1728 | ChEMBL_ID |
C053091 | MESH_SUPPLEMENTAL_RECORD_UI |
12407 | IUPHAR_LIGAND_ID |
6222 | INN_ID |
DB00978 | DRUGBANK_ID |
L6BR2WJD8V | UNII |
235762 | RXNORM |
4990 | MMSL |
d00104 | MMSL |
003642 | NDDF |
003643 | NDDF |
387553002 | SNOMEDCT_US |
412239000 | SNOMEDCT_US |
96088001 | SNOMEDCT_US |
C0065162 | UMLSCUI |
3948 | PUBCHEM_CID |
None